Cellular Intelligence Secures Global Rights to Novo Nordisk’s Parkinson’s Cell Therapy Program and Receives Equity Investment

Deal Summary

Cellular Intelligence announced an agreement with Novo Nordisk to obtain global rights to the pharma giant’s clinical-stage allogeneic cell therapy for Parkinson’s disease. Novo Nordisk will also become an equity investor in Cellular Intelligence, with rights to future milestones and royalties. The partnership leverages Cellular Intelligence’s AI platform to accelerate development and manufacturing.